UCB

Overview

UCB (Union Chimique Belge) was founded on 18 January 1928 by Emmanuel Janssen in Brussels. The company started in industrial chemistry and gradually moved into pharmaceuticals through Meurice Laboratories, with an early research center established in the 1950s producing medicines such as Atarax. Over the following decades UCB transitioned from a diversified chemicals group into a focused biopharmaceutical company.

Today UCB is one of the largest Belgian companies on Euronext Brussels and a member of the Bel20 index. Its commercial portfolio centers on neurology (Vimpat, Briviact, Keppra) and immunology (Cimzia, Bimzelx), with a research footprint that spans Belgium, the United Kingdom, the United States and Japan. Headquarters are in the Anderlecht district of Brussels.

Jean-Christophe Tellier joined UCB in 2011 and became CEO on 1 January 2015. The Board has proposed renewing his mandate as CEO and director through 2030.

Listing

• Euronext Brussels: UCB (Bel20)

Links

• Website: https://www.ucb.com
• LinkedIn: https://linkedin.com/company/ucb

Media & appearances

• De TijdYouTube2026-06-19
  Alexander Roose (Argenta): 'Ik zie vandaag mooie kansen in de sector van de voedingsingrediënten'Belgian pharma stalwart with a strong track record of getting drugs past the FDA, noted as attractive from a long-term perspective.
• De CFO PodcastYouTube2025-04-19
  De CFO Podcast x SuperNova #11 | Matthew KonnehBelgian biotech company Konneh has dealt with in the past, cited as an example of Belgium's thriving biotech scene.
• ConnexiYouTube2024-02-05
  #69 Anouk van Oordt (Out Of Office) over keuzes makenClient in Anderlecht whose office atmosphere prompts visitors to ask 'who is the mastermind behind this', generating referrals.